Institute for Experimental Cellular Therapy, University Hospital Essen, Germany.
Best Pract Res Clin Haematol. 2024 Sep;37(3):101575. doi: 10.1016/j.beha.2024.101575. Epub 2024 Aug 28.
Mismatching at the HLA-DPB1 locus occurs frequently in hematopoietic cell transplantation with unrelated donors. Despite this, HLA-DPB1 allelic mismatches have traditionally not been considered in patient-donor matching. A T-cell epitope (TCE) model for the functional assessment of permissive mismatches at this locus has nevertheless been adopted in clinical practice. While initially based on a hierarchical immunogenicity elucidated from allorecognition by T-cell clones isolated from a patient, newer developments in the understanding of this model's biological basis, including a central role for immunopeptidome divergence between mismatched allotypes, have prompted changes in the assignment of permissiveness, providing the opportunity for a more granular evaluation of graft-versus-host disease and relapse risks according to the nature and directionality of permissive mismatches. How these advances impact the assessment of permissiveness at HLA-DPB1 and potentially the intelligent selection of donors according to the main clinical goal for different patients is the subject of the present review.
HLA-DPB1 位点错配在异基因造血细胞移植中很常见。尽管如此,HLA-DPB1 等位基因错配在患者-供体匹配中传统上并未被考虑。然而,在临床实践中已经采用了 T 细胞表位 (TCE) 模型来对该位点的允许性错配进行功能评估。虽然最初是基于从患者分离的 T 细胞克隆的同种异体识别中阐明的分层免疫原性,但对该模型生物学基础的理解的最新进展,包括免疫肽组在错配异型中的差异的核心作用,促使允许性的分配发生变化,根据允许性错配的性质和方向性,为移植物抗宿主病和复发风险提供了更细致的评估机会。这些进展如何影响 HLA-DPB1 允许性的评估,并根据不同患者的主要临床目标智能选择供体,是本综述的主题。